
Press Release

28 June 2019

Immunicum AB (publ) Announces New Issuance Date for Interim Report April – June 2019 and Corporate Update Event

- Interim Report April – June 2019 to be published on Tuesday, August 20, 2019
- Company to host corporate update event on that date and additional events in the second half of 2019

Immunicum AB (publ) has rescheduled the issuance date of the Interim Report April - June 2019 to Tuesday, August 20, 2019. The previously communicated date for the Interim Report was Friday, August 23, 2019.

The Interim Report issuance date was adjusted to facilitate an Immunicum-hosted corporate update event in which CEO, Carlos de Sousa and CFO, Michaela Gertz, as well as other members of the management team, will present details from the Interim Report during an extended corporate presentation, discuss Immunicum's position in the immuno-oncology field as well as provide an update on the Company's clinical development program and general corporate strategy. This event will be held in advance of the Phase II MERECA clinical trial top line results announcement. The data are expected to be disclosed to Immunicum from the Clinical Research Organization during the first week of September 2019. Once receiving the data, Immunicum will soon thereafter publish a press release to publicly share the top line results.

Corporate Update Event Information

Date: Tuesday, August 20, 2019

Time: 13.00 – 15.00 Central European Time

Location: Mäster Samuelsgatan 42, Stockholm, Sweden ; 10th Floor

The event will also be available via livestream and will remain accessible in video format following the completion of the event. The link to the livestream and video will be posted on the Immunicum corporate website: www.immunicum.se

In addition to the corporate update event in August, Immunicum will host the events listed below in the second half of 2019. Further details will be shared closer to the start of each event.

- A webcast in the first week of September following the announcement of the top line results of the Phase II MERECA clinical trial which are anticipated to be released within that timeframe.
- A Capital Markets Day in November 2019 held in Stockholm to discuss the Interim Report July – September 2019.

FOR MORE INFORMATION, PLEASE CONTACT:

Carlos de Sousa, CEO, Immunicum

Telephone: +46 8 732 8400

E-mail: info@immunicum.com

Michaela Gertz, CFO, Immunicum

Telephone: +46 70 926 17 75

E-mail: ir@immunicum.com

MEDIA RELATIONS

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

U.S. AND INTERNATIONAL INVESTOR RELATIONS

Thomas Renaud
Arrowhead Business and Investment Decisions, LLC
Telephone: +1 212 619-6889 or +1 917 370-5879
E-mail: thomas.renaud@arrowheadbid.com
Immunicum abid.co page: www.abid.co/OMX.IMMU

SWEDISH INVESTOR RELATIONS

Jonas Rodny and Carolin Wiken
Paues Åberg Communications
Telephone: +46 190 90 51
E-mail: jonas.rodny@pauesaberg.se or carolin.wiken@pauesaberg.se

ABOUT IMMUNICUM AB (PUBL)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com